Well, it is
not funny anymore. FDA
Staff Questions Benefits of Glaxo, Merck Cancer Drugs. Whom to blame? A lot
of resources were spent on those two projects, a lot of hope. And in vain.
Let’s
investigate the situation closely:
Votrient and the Merck-Ariad
drug, which might be called Taltorvic if approved, would be the first targeted
treatments for a cancer that invades soft tissue such as muscle, tendons
and fat outside the stomach and intestines.
Targeted
treatment again! And if so they had to be developed according to the same HTS paradigm
and methodology. Probably we need to leave some space for “cautious regulators”problem but we absolutely will not lay all the responsibility for the inefficacy
of these drugs on the FDA. The rules are extremely strict but hopefully still
fair.
Due to
there is no shift in paradigm expected in the nearest future I am afraid we
will see more cases of fall of targeted drugs. Time will show. Only time.
No comments:
Post a Comment